Jul 3 |
GSK to Buy CureVac’s Covid-19, Flu Vaccine Rights for Up to $1.56 Billion
|
Jul 3 |
GSK and CureVac restructure mRNA vaccine development deal
|
Jul 3 |
CureVac Enters Into New Licensing Agreement With GSK; to Implement 'Significant' Restructuring; Shares Rise Pre-Bell
|
Jul 3 |
CureVac to cut 30% of workforce as GSK buys rights to make flu, covid shots
|
Jul 3 |
GSK and CureVac to Restructure Collaboration into New Licensing Agreement
|
Jul 3 |
CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
|
Jul 3 |
GSK buys COVID, influenza vaccines from retrenching CureVac
|
Jun 24 |
CureVac Announces Voting Results of General Meeting
|
Jun 6 |
First Human Death From Bird Flu Strain Puts Vaccine Stocks Back On The Map
|
May 30 |
Third human bird flu case found in U.S.
|